ライフサイエンスコーパス: upfront

1 ert consensus to warrant a 2-stent technique upfront.

2 chnically could undergo a surgical resection upfront.

3 ic profiling to identify those at risk of ER upfront.

4 ion for MCL patients and is now being tested upfront.

5 ore with patients whose tumors were resected upfront.

6 e considered in younger patients if not used upfront.

7 would have been randomized to undergo either upfront (18)F- or (68)Ga-PSMA PET staging or conventiona

8 and neck squamous cell carcinoma (HNSCC) by upfront (18)F-FDG PET/CT (i.e., on the day of biopsy and

9 d 693 (84.9%) had postoperative radiotherapy upfront; 36.8% of 3-year-olds and 4.1% of 8-year-olds ha

10 sed mortality, but reversal is possible with upfront adrenal androgen blockade.

11 have tested one of three approaches: (1) an upfront AI, (2) a sequential approach after 2-3 years of

12 However, clustering requires upfront algorithm and hyperparameter selection, which ca

13 ients for optimal doses and/or modalities of upfront AML therapy.

14 d), or loss incentive ($42 allocated monthly upfront and $1.40 removed each day the goal was not achi

15 free survival was 66.5% for patients treated upfront and 41.4% for relapsed patients.

16 However, the development of upfront and acquired resistance poses substantial challe

17 -free survival rates for patients undergoing upfront and delayed enucleation were 0.89 +/- 0.03 and 0

18 The upfront and delayed groups each included 301 patients.

19 y to platinum-based chemotherapy in both the upfront and recurrent setting, and have an overall impro

20 reatment and as a maintenance therapy in the upfront and recurrent settings.

21 ent of ziftomenib combination therapy in the upfront and relapsed or refractory setting is ongoing.

22 herapies, including immunotherapeutics, into upfront and salvage regimens and the role of hematopoiet

23 onable treatment for WM patients in both the upfront and salvage settings, though randomized studies

24 nd Drug Administration (FDA) approved in the upfront and the recurrent setting.

25 brought proximal, this must be screened for upfront, and (b) cooperative or synergistic interactions

26 is of incremental data availability owing to upfront application of omics technologies, a more granul

27 With a more upfront approach to DKT by offering this option to patie

28 Larger CD34 quantities should be collected upfront as the risk of MDS could be reduced by applying

29 se-positive anaplastic large cell lymphoma), upfront auto-SCT was associated with a superior OS (HR,

30 significant event-free survival advantage to upfront autologous transplantation compared with interfe

31 or low RDI should be identified and targeted upfront before initiating chemotherapy.

32 etermine whether these patients benefit from upfront biventricular pacing.

33 tcomes in the largest AL cohort treated with upfront bortezomib and explore the impact of posttreatme

34 Upfront bortezomib confers durable hematologic responses

35 on ongoing maintenance subsidies rather than upfront capital cost subsidies.

36 The upfront capital costs are almost 5-fold lower for the iS

37 d zinc (Zn) propellant engine segment and an upfront cargo-loaded gelatin segment further protected b

38 findings highlight the necessity for careful upfront cellular enrichment in biospecimens that form th

39 In the scenario comparing upfront CGP and standard-of-care diagnostics, the increm

40 elevant to the inclusion of anthracycline in upfront chemoimmunotherapy for these elderly patients an

41 eeks after vector administration and standad upfront chemoradiotherapy.

42 ABC DLBCL has a worse survival after upfront chemotherapy and is characterized by constitutiv

43 Patients must have received upfront chemotherapy and up to two prior chemotherapy re

44 tly improved survival outcomes compared with upfront chemotherapy or targeted therapy.

45 ceived upfront PRRT and 179 (35.2%) received upfront chemotherapy or targeted therapy.

46 firmed type II and type III PPB who received upfront chemotherapy were enrolled; 132 children (75 wit

47 myelogenous leukemia achieve remission with upfront chemotherapy, many patients still suffer relapse

48 from postmastectomy radiation therapy after upfront chemotherapy.

49 GCB DLBCL have equally poor survivals after upfront chemotherapy.

50 medulloblastoma into the next generation of upfront clinical trials, with the goal of both improving

51 s use to evade drug response, the promise of upfront combination and intermittent therapies and thera

52 al rate of 6% despite promising responses to upfront combination chemotherapy.

53 cs at diagnosis, were more likely to receive upfront combination pulmonary arterial hypertension ther

54 These data suggest that upfront combination strategies targeting EGFR amplificat

55 guide therapy as treatment of patients with upfront combination therapy was clearly superior in RAS/

56 iated RAS-mTOR signaling and is prevented by upfront combination therapy with PLX8394 and either an E

57 We further demonstrate that upfront combined inhibition of FAK and Src synergistical

58 In this study of patients with upfront, complete resection of node-positive esophageal

59 abase was queried for patients who underwent upfront, complete resection of pT1-4N1-3M0 esophageal ad

60 of bleeding, implantation is associated with upfront complications.

61 cycline-based chemotherapies with or without upfront concurrent chemoradiotherapy or radiotherapy wit

62 h-risk areas are excluded) but also increase upfront conservation costs.

63 icin, vincristine, and prednisone (CHOP) and upfront consolidation with autologous stem cell transpla

64 elective neck dissection comes with greater upfront cost and patient morbidity.

65 teral vs 224 bilateral) because of the large upfront cost of the implant.

66 sts remained higher with TMVr because of the upfront cost of the index procedure ($73 416 versus $38

67 uencing technologies, largely due in part to upfront cost, ease-of-use, and access to expertise.

68 the advantages of gasoline automobiles: low upfront cost, long driving range and fast refuelling.

69 deductible health plans (HDHPs) require high upfront cost-sharing, which has been associated with sub

70 However, high upfront costs and variable cashflows are obstacles for m

71 Large upfront costs of a single administration cure are offset

72 wer purchase agreements, especially when the upfront costs of solar are high.

73 y on proprietary systems that may have large upfront costs or present frameworks that require customi

74 Object oriented designs, though has upfront costs, are practical now and can provide such an

75 Despite upfront costs, DLBCL treatment is probably a prudent inv

76 , conventional fabrication methods have high upfront development expenses with slow mold fabrication

77 ositive indications for malignant disease in upfront diagnosis.

78 Upfront doxycycline is a rational and active treatment f

79 only in ocular adnexal MALT lymphomas where upfront doxycycline may be a reasonable and effective in

80 Experimental modeling further suggests that upfront dual inhibition of TRK and MEK may delay time to

81 stepwise provisional strategy (n=230) or an upfront dual-stent approach (n=237).

82 ain (LM) bifurcations was more frequent with upfront dual-stenting compared with the stepwise provisi

83 men), 31 were randomized to and treated with upfront dual-stenting, while 17 were randomized to the s

84 and exclusively involves the use of cytoxics upfront (e.g., radiation and chemotherapy).

85 e PLC signalosome in B-ALL by Dex limits the upfront efficacy of this chemotherapeutic agent.

86 tional analysis demonstrated that the use of upfront EGFR-TKI, and deferral of radiotherapy, is assoc

87 primary surgical extirpation with or without upfront elective neck dissection.

88 subclinical nodal disease in these patients, upfront elective neck dissections (END) for patients wit

89 Overall, this technology is a multiplexable upfront enrichment applicable with multiple downstream m

90 nsitivity, specificity and typically require upfront enrichment, ligation and/or amplification steps.

91 d the use of adjuvant chemotherapy following upfront enucleation and diagnosis of HRHF.

92 ilateral IRSS stage I disease; 102 underwent upfront enucleation, and 59 had delayed enucleation.

93 g System [IRSS] stage I) were considered for upfront enucleation.

94 The results show that upfront environmental and economic investments are neede

95 nts with clinical T1-3N0M0 cancer undergoing upfront esophagectomy from 2004 to 2014.

96 as few as one million reads, allowing for an upfront evaluation of the sample integrity before whole

97 Larger scale, upfront funding for evaluation of health financing initi

98 One way to do this that would not require upfront funding is to change the policies that regulate

99 On a population level, upfront genotyping seemed cost saving.

100 At month 12, LS BMD was 4.4% higher in the upfront group than in the delayed group (95% CI, 3.7% to

101 In the upfront group, mean serum N-telopeptide and bone-specifi

102 algorithm that, instead of fixing an ansatz upfront, grows it systematically one operator at a time

103 or to glucose exhaustion experience a larger upfront growth cost but also a shorter diauxic lag.

104 Patients treated upfront had higher rates of CR (65.0%) and VGPR-dFLC (66

105 Consolidation involved either upfront haematopoietic stem-cell transplantation (HSCT)

106 gnated as having "postoperative radiotherapy upfront" if they received radiotherapy within 90 days of

107 ombination with androgen-deprivation therapy upfront in advanced or high-risk prostate cancer.Tumours

108 Therefore, PEGasparaginase should be used upfront in induction, and we suggest that the dose could

109 nd neck MRI (CHCT/MRI) with (18)F-FDG PET/CT upfront in the diagnostic workup of patients with oral,

110 ge, 65 years; range, 32 to 87 years) treated upfront in the trials MCL Younger or MCL Elderly were po

111 ating surgically correctable PA outweigh the upfront increased costs in patients at the time patients

112 enocarcinoma and provide a rationale for the upfront inhibition of both ALK and MEK to forestall resi

113 Upfront inhibition of both ALK and the kinase MEK enhanc

114 The indications for upfront laryngectomy in the management of laryngeal canc

115 in 382 HCC patients without PVTT undergoing upfront LDLT (5-y OS 65%, P = 0.06; RFS 66%, P = 0.33, r

116 h early hepatocellular carcinoma (HCC-cirr), upfront liver resection (LR) and salvage liver transplan

117 hepatocellular carcinoma could benefit from upfront liver resection (LR) or liver transplantation (L

118 carcinoma (HCC) patients, to try to obviate upfront liver transplantation, with the "safety net" of

119 Of 130 HCC-cirr patients who underwent upfront LR (group LR), 90 (69%) recurred, 31 could under

120 rence (NTR) to improve patient selection for upfront LR or LT at initial diagnosis.

121 ention-to-treat tumor-related survival after upfront LT rather than LR.

122 tterns reflect the differing payment models: upfront lump-sum payments (cooperative group) versus mil

123 east carcinoma from 2012-2016 that underwent upfront lumpectomy and were found to have a positive sen

124 After upfront mastectomy, PMRT is indicated for most patients

125 digm and is currently being expanded with an upfront multicategorical approach following recent advan

126 Although none of the patients transplanted upfront (n = 117) developed clonal complications (either

127 seemed inferior when compared with approved upfront nivolumab plus ipilimumab.

128 was used to identify patients who underwent upfront nodal dissection for mucosal head and neck squam

129 ays for a matched cohort of patients with an upfront open procedure.

130 phamide, bortezomib, and dexamethasone (CVD) upfront or at relapse.

131 ole were randomly assigned to receive either upfront or delayed-start zoledronic acid (4 mg intraveno

132 hort, but was relevant in certain subgroups (upfront pancreatectomy (n = 117; P = 0.049); without VR

133 mm for the SMA-margin in specific subgroups (upfront pancreatectomy, N0 patients without NAT, N+ pati

134 ase groups studied here, thus questioning an upfront pathological role of these serum AB.

135 Conclusions and Relevance: Nephrectomy after upfront pazopanib therapy could be performed safely and

136 ive: To establish the safety and efficacy of upfront pazopanib therapy prior to cytoreductive nephrec

137 Patients who underwent upfront PD at two academic institutions between 2000 and

138 m the National Cancer Database who underwent upfront PDAC resection from 2010 to 2014 were analyzed t

139 Upfront phase II window trials can efficiently provide r

140 Routine use of EN is preferable to upfront PN in these patients.

141 278 [54.7%] were male), 329 (64.8%) received upfront PRRT and 179 (35.2%) received upfront chemothera

142 In this cohort study, treatment with upfront PRRT in patients with enteropancreatic neuroendo

143 After adjustment of values for interaction, upfront PRRT was associated with longer PFS regardless o

144 However, upfront R-CHOP may benefit selected high-risk cases in w

145 t for active surveillance exceeded that from upfront radical prostatectomy after 3-5 years of follow-

146 rticipants were randomized to receive either upfront radiosurgery (n = 50) or to undergo a wait-and-s

147 or volume reduction in patients treated with upfront radiosurgery (wait-and-scan to upfront radiosurg

148 all- and medium-sized vestibular schwannoma, upfront radiosurgery demonstrated a significantly greate

149 an V4:V0 was 0.87 (95% CI, 0.66-1.15) in the upfront radiosurgery group and 1.51 (95% CI, 1.23-1.84)

150 In the upfront radiosurgery group, 1 participant (2%) received

151 sized vestibular schwannoma recommend either upfront radiosurgery or waiting to treat until tumor gro

152 with upfront radiosurgery (wait-and-scan to upfront radiosurgery ratio, 1.73; 95% CI, 1.23-2.44; P =

153 common standard arm combined with a general upfront randomization and performed prospective analyses

154 ontinuation design is more powerful than the upfront randomization design when the treatment effect i

155 ntinuation design is more efficient than the upfront randomization design when treatment benefit is r

156 power of the randomized discontinuation and upfront randomization designs under two models for the t

157 power of the randomized discontinuation and upfront randomization designs under two previously propo

158 iscontinuation design is not as efficient as upfront randomization if treatment has a fixed effect on

159 oximately 1 hour, he elected to proceed with upfront RC and extended lymph node dissection in conjunc

160 serve as financial intermediaries to pay the upfront recovery expenses for deceased donor kidneys bef

161 Upfront reflux monitoring off acid suppression can limit

162 stablish consensus classification and assess upfront resectability.

163 rline resectable PDAC) may be preferable for upfront resectable PDAC.

164 ed with neoadjuvant FOLFIRINOX compared with upfront resected patients (DFS: 29.1 vs 13.7, P < 0.001;

165 tly longer in pN0 versus pN1 patients in the upfront resected patients (median 16 mo pN0 vs. 10 mo pN

166 in site of first recurrence or metastasis in upfront resected patients, nor in neoadjuvant-treated pa

167 ents who received neoadjuvant FOLFIRINOX and upfront resected patients.

168 3.4 vs 5.6%, p = 0.004) were associated with upfront resection (n = 134, 19.9%).

169 followed by resection and those who received upfront resection (UR)-as well as a subgroup of UR patie

170 tern was consistent in patients treated with upfront resection and adjuvant chemotherapy (DM 83.0%, L

171 With upfront resection and adjuvant therapy an actual overall

172 ons for resectable pancreatic cancer support upfront resection and adjuvant therapy.

173 Upfront resection and microvascular tumor invasion were

174 Upfront resection decreased over time and 15.4% of patie

175 All patients undergoing upfront resection for resectable and borderline-resectab

176 Patients were divided into an upfront resection group (n = 394) and a neoadjuvant grou

177 We included 16,709 patients who underwent upfront resection of PDAC.

178 ival advantage over chemotherapy alone after upfront resection of PDAC.

179 Patients who have upfront resection typically receive a total of 4-6 cycle

180 nhibitor (ICI) regimens may help to overcome upfront resistance and mitigate the risk for immune-rela

181 Upfront resistance to chemotherapy and relapse following

182 hy only ~50% of BRCA-mutant patients display upfront resistance.

183 Despite frequent upfront responses, acquired resistance has compromised l

184 known, some centres offer multiagent therapy upfront, resulting in overtreatment of many patients.

185 essel disease, EES was associated with lower upfront risk of death and stroke when compared with coro

186 Despite upfront risks, long-term survival is highest for patient

187 h to eradicate PVCs but may confer increased upfront risks.

188 ryngeal swab specimens stored in UTM without upfront RNA extraction.

189 failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard me

190 Upfront screening for these variants, in addition to the

191 ne, and dacarbazine (AVD) is approved in the upfront setting for advanced stage classical Hodgkin lym

192 ility of ASCT and use of novel agents in the upfront setting of multiple myeloma and pPCL began after

193 th increasing use of the novel agents in the upfront setting, several reports have emerged raising co

194 al risk, we further propose consideration of upfront simultaneous use of vericiguat (ie, quintuple me

195 ly negative nodes has an accuracy similar to upfront SLNB and reduces the need for axillary lymph nod

196 We examined the impact of upfront small bowel resection (USBR) for metastatic SB-N

197 -related haemorrhage and (3) management with upfront SRS (intervention group) or conservative managem

198 e managed conservatively and 169 (55.6%) had upfront SRS.

199 nd whole brain radiotherapy, and the role of upfront stereotactic radiosurgery for BrM.

200 as there a significant difference in OS with upfront steroids (26.1 vs. 15.6 months, p = .032).

201 s a classical randomized clinical trial with upfront stratification for the marker.

202 lude that our PET radiomic model may improve upfront stratification of early-stage HL patients with m

203 3-15 (n=1297), adding GFAP and UCH-L1 to the UPFRONT study model modestly increased the AUC for predi

204 tients who underwent neoadjuvant therapy and upfront surgery (88% vs 84%, P = 0.08).

205 s associated with prolonged OS compared with upfront surgery (adjusted hazard ratio 0.69, 95% confide

206 t treatment (experimental arm) or undergoing upfront surgery (control arm).

207 neoadjuvant chemoradiotherapy (n = 119) and upfront surgery (n = 127).

208 erived pancreatic cancer treated with either upfront surgery (US) or NAT were identified from eight i

209 ulation with poor outcomes when treated with upfront surgery alone.

210 44 patients, among whom 460 (44.1%) received upfront surgery and 584 (55.9%) received CRT.

211 juvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable a

212 prove operability and clinical outcomes over upfront surgery and adjuvant therapy, and has become an

213 16.8% of AIs underwent upfront surgery and rest initial nonoperative management

214 16.7 months (95% CI 11.6-22.2 months) in the upfront surgery arm.

215 For resectable pancreatic cancer, upfront surgery followed by adjuvant therapy has long be

216 It suggests that upfront surgery followed by postoperative anti-TNF thera

217 Once solely reliant on upfront surgery followed by stage and pathology-driven a

218 adjuvant chemoradiotherapy group than in the upfront surgery group (hazard ratio, 0.73; 95% CI, 0.56

219 Patients in the upfront surgery group underwent surgery followed by six

220 ed (1:1) to neoadjuvant chemoradiotherapy or upfront surgery in 16 Dutch centers.

221 es R0 rates and overall survival compared to upfront surgery in R/BR-PDAC patients.

222 Upfront surgery is usually recommended for tumors larger

223 local-regional control with BCT with either upfront surgery or surgery after neoadjuvant chemotherap

224 Lack of OS benefit with upfront surgery persisted in a subset analysis of patien

225 In the upfront surgery setting, 296 of 335 patients (88.4%) had

226 disease, median OS for patients treated with upfront surgery was 28 months, compared to 15 months in

227 On multivariable Cox regression, upfront surgery was not associated with increased OS whe

228 th incompletely resected NSCLC who underwent upfront surgery with positive surgical margins followed

229 o mastectomy: (1) indications for PMRT after upfront surgery, (2) indications for PMRT after neoadjuv

230 After upfront surgery, 72% of patients received adjuvant chemo

231 In 54 participants who underwent upfront surgery, MRI showed a higher reliability with su

232 from postmastectomy radiation therapy after upfront surgery, no such data exist for guiding decision

233 y improved event-free survival compared with upfront surgery, supporting a shift toward a sequential

234 imary surgery, whereas 13 patients underwent upfront surgery.

235 otherapy and 6.5% (95% CI, 3.1 to 13.7) with upfront surgery.

236 wed by surgical resection, and 184 underwent upfront surgery.

237 5.67 vs. 12.83 months, P=0.0197) compared to upfront surgery.

238 reatment in patients qualifying for elective upfront surgery.

239 as associated with improved OS compared with upfront surgery.

240 of 47% versus 35% (P = 0.0001) compared with upfront surgery.

241 pathologic staging in individuals undergoing upfront surgery.

242 pN0 patients as compared with pN1 patients, (upfront surgery: 55% vs. 77%, P < 0.001 and 64% vs. 78%,

243 and compare short-term outcomes to those of upfront surgical management.

244 Primary treatment with an upfront surgical procedure was associated with a decreas

245 al cavity squamous cell carcinoma undergoing upfront surgical resection for curative intent were iden

246 In the present analysis, we examine whether upfront surgical resection improves overall survival in

247 tion of micrometastatic disease, correct and upfront surgical staging of the inguinal lymph nodes is

248 Definitive chemoradiotherapy and upfront surgical treatment are both accepted as the stan

249 y group and 486 patients (41.2%) were in the upfront surgical treatment group.

250 ee survival was worse in the group receiving upfront surgical treatment than in the group receiving c

251 tological grade, and T and N classification, upfront surgical treatment was no longer associated with

252 Definitive chemoradiotherapy or upfront surgical treatment.

253 C occurred even in the absence of T, so the upfront T does not explain the loss of C.

254 implementation was associated with more net upfront tests yet fewer net stress tests, PCI, cardiolog

255 eukemia, upfront therapy, upfront therapies, upfront therapeutic, upfront therapeutics, upfront treat

256 apy, upfront therapies, upfront therapeutic, upfront therapeutics, upfront treatment, front-line trea

257 ronic lymphocytic leukemia, upfront therapy, upfront therapies, upfront therapeutic, upfront therapeu

258 ients with myelodysplastic syndrome received upfront therapy (14 haematopoietic stem cell transplanta

259 n in more than 2 decades despite advances in upfront therapy and improved survival for de novo ALL.

260 those 19, 18 were relapsed or refractory to upfront therapy and referred for stem cell transplantati

261 Optimal upfront therapy for posttransplant lymphoproliferative d

262 in a low-dose, 5-day regimen has activity as upfront therapy in older patients with AML, and it has a

263 e an urgent need not only for more effective upfront therapy to prevent relapse, but also for the dev

264 g the keywords chronic lymphocytic leukemia, upfront therapy, upfront therapies, upfront therapeutic,

265 es and Europe in terms of its use as part of upfront therapy.

266 However, the resampling must not be applied upfront to all data because it would lead to data leakag

267 ght support the use of combination therapies upfront to maximise response and improve outcomes as is

268 he TT approach uses all myeloma-active drugs upfront to target drug-resistant subclones during initia

269 may allow directing more aggressive therapy upfront to the patients most likely to benefit while spa

270 eriences, which involve intensive amounts of upfront training, human error with limited quality contr

271 In the presence of 2 factors or more upfront transplantation should be probably preferred to

272 little effect on primary human tumors during upfront treatment but can eliminate neuroblastoma cells

273 Upfront treatment of acute TTP includes plasma exchange

274 idomide becomes increasingly established for upfront treatment of multiple myeloma, patients refracto

275 : Our data provide a proof of principle that upfront treatment with the BGJ398 + ganetespib combo imp

276 , upfront therapeutic, upfront therapeutics, upfront treatment, front-line treatment, first-line trea

277 hat extent these patients require aggressive upfront treatment.

278 established and incorporation of adjunctive upfront treatments such as chemotherapy and novel anti-a

279 assessed the cardiovascular safety of AIs as upfront treatments, their cardiotoxicity as sequential t

280 The US community-based, phase IIIB UPFRONT trial was designed to compare three frontline bo

281 Even so, upfront tumor eradication is frequently not achieved wit

282 course of treatment appear to be superior to upfront tumor resection.

283 Upfront tumour genotyping is now considered an essential

284 Participants were randomly assigned 1:1 to upfront ultrasound-guided pleural pigtail catheter thora

285 ators, (3) comparative efficacy of top-down (upfront use of biologics and/or immunomodulator therapy)

286 ive, HER2-negative metastatic breast cancer, upfront use of chemotherapy remains common even in the a

287 h non-anthracycline-based chemotherapies and upfront use of concurrent chemoradiotherapy or radiother

288 inotecan at first progression (arm A) versus upfront use of fluoropyrimidine plus irinotecan plus bev

289 y to minimise chemotherapy exposure, because upfront use of these targeted therapies could result in

290 Here, we used one such strategy, upfront voluntary choice restriction ('precommitment'),

291 r those receiving postoperative radiotherapy upfront vs postoperative radiotherapy deferred (5-year O

292 ufficient data to resolve the controversy of upfront WBRT versus SRS in the management of patients wi

293 Children's Oncology Group has conducted five upfront window trials in patients with newly diagnosed m

294 n days 1-5 and 8-12 of a 21-day cycle) in an upfront window; those with complete (CR) or partial resp

295 eduction of PVR in patients with PAH treated upfront with a combination of oral drugs.Methods: The st

296 xel upon radiographic progression (arm 1) or upfront with AAP + C (arm 2).

297 ational cure, especially if they are treated upfront with anti-CD38 antibody-based therapy but also w

298 y prostate cancer (PCa) patients are treated upfront with AR-targeted agents, it is critical to ident

299 al Registry should have its aims established upfront, with appropriate governance and oversight, and

300 djuvant Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in th